Developmental Research Program

发展研究计划

• 批准号: 8999526
• 负责人: Timothy Charles Thompson
• 金额: $ 7.52万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-02 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8999526
• 关键词: Area; Award; Awareness; Basic Science; Cancer Center; Cancer Patient; Clinical Research; Collaborations; Communities; Complement; Development; Educational Activities; Environment; Evaluation; Funding; Funding Mechanisms; Goals; Grant; Human; Incidence; Institution; K-Series Research Career Programs; Laboratories; Leadership; Letters; Malignant neoplasm of prostate; Minority; Modeling; Monitor; National Cancer Institute; Participant; Peer Review Grants; Pilot Projects; Population; Principal Investigator; Process; Program Research Project Grants; Progress Reports; Publications; Qualifying; Quality of life; Recruitment Activity; Research; Research Personnel; Research Project Grants; Research Support; Scientist; Selection Criteria; Survival Rate; Translating; Translational Research; United States National Institutes of Health; Woman; Writing; anticancer research; base; cancer survival; career; flexibility; improved; innovation; meetings; member; mortality; organizational structure; programs; research study; success

PROJECT SUMMARY (Developmental Research Program) The goal of the Developmental Research Program (DRP) of the MD Anderson Cancer Center Prostate Cancer SPORE is to fund promising studies in translational prostate cancer research. It is directed by Dr. Timothy C. Thompson and co-directed by Dr. Christopher J. Logothetis. As with our current SPORE, the DRP in this renewal will emphasize the support of translational research studies that can generate clinically testable hypotheses to help reduce the incidence and mortality of prostate cancer and/or improve the quality of life of prostate cancer patients. The Prostate Cancer SPORE Administrative Core has established a broad-based effort for solicitation of potential DRP projects. Letters of intent of no more than 2 pages for innovative translational research are invited from MD Anderson and outside institutions and SPORE and non-SPORE investigators, including participants in the SPORE Career Enhancement Program. These applications will be screened by the program Director and co-Director (who also serve as the SPORE Principal investigator and co-Principal Investigator) according to objective criteria. Investigators of selected applications will be asked to prepare a 5-page proposal modeled after a National Institutes of Health R01. As appropriate, the Administrative Core Directors and staff will assist investigators submitting proposals formulate translational specific aims and research plans, as many of these investigators will not have expertise in these areas. The process constitutes a major educational activity and will further stimulate the development of innovative translational research concepts. The proposals will be reviewed and prioritized by the Prostate Cancer SPORE Leaders (Principal Investigators, Project co-Leaders, Program Directors, and Core Directors). The projects will be funded for 1 year and will be renewable for an additional year on the basis of established criteria. Developmental Research projects will be evaluated ad hoc and annually by the program Director/co- Director, SPORE Leaders, Executive Committee, and combined Internal/External Advisory Boards. The DRP has established a mechanism for termination of projects that do not meet our criteria for continuation; however, it has not been necessary to utilize this mechanism in the DRP to date. Nine developmental projects were funded in the current Prostate Cancer SPORE. Investigators receiving DRP grants wrote 29 publications related to the research supported by their grants during 2009-2014 and were awarded 19 external peer-reviewed grants. Importantly, 2 DRP awardees are investigators for major projects in the Prostate Cancer SPORE renewal application: Drs. Sue-Hwa Lin (co-Leader, Project 2) and Padmanee Sharma (co-Leader, Project 1), highlighting the importance of the DRP in identifying projects and investigators with potential value for translational research.

项目摘要（发展研究计划） MD安德森癌症中心前列腺发展研究计划（DRP）的目标 癌症孢子将资助在转化前列腺癌研究中的有希望的研究。它是由博士指导的 蒂莫西·C·汤普森（Timothy C. Thompson），由克里斯托弗（Christopher J.与我们目前的孢子一样，DRP 在此续签中，将强调可以产生临床测试的翻译研究的支持 假设有助于降低前列腺癌的发病率和死亡率和/或提高生活质量 前列腺癌患者。前列腺癌孢子行政核心已经建立了一个广泛的基础 为潜在的DRP项目征集的努力。创新的意向书不超过2页 MD Anderson以及外部机构以及孢子和无孢子的转化研究邀请了翻译研究 调查人员，包括孢子职业增强计划的参与者。这些申请将是 由计划主任兼联合导演筛选（他还担任孢子首席研究员和 共同主管研究者）根据客观标准。选定申请的调查人员将被要求 准备以卫生研究院R01为基础的5页提案。适当的 行政核心主管和员工将协助调查人员提交提案，提出翻译 具体的目标和研究计划，因为许多研究人员将在这些领域没有专业知识。这 过程构成了一项主要的教育活动，并将进一步刺激创新的发展 翻译研究概念。这些提案将被前列腺癌审查和优先级 孢子领导者（主要研究人员，项目共同领导者，计划主管和核心董事）。这 项目将获得1年的资金，并将在既定的基础上续签一年 标准。计划主任/共同将对发展研究项目进行临时评估 孢子领导人，执行委员会主任和内部/外部咨询委员会合并。 DRP 已经建立了一种终止不符合我们延续标准的项目的机制； 但是，迄今为止，在DRP中没有必要在DRP中使用这种机制。 在当前的前列腺癌孢子中资助了9个发展项目。接收DRP的调查人员 格兰特（Grants 授予19个外部同行评审的赠款。重要的是，2名DRP获奖者是主要项目的调查员 在前列腺癌孢子的更新应用中：Drs。 Sue-Hwa Lin（共同领导，项目2）和Padmanee Sharma（共同领导，项目1），强调了DRP在识别项目和调查人员方面的重要性 具有转化研究的潜在价值。